Earnings ·
Reviva Pharmaceuticals Holdings reported a net loss of $2.4 million ($0.19 per share) for the second quarter ended…
RVPHWReviva Pharmaceuticals Holdings, Inc.
Reviva Pharmaceuticals Holdings reported a net loss of $2.4 million ($0.19 per share) for the second quarter ended June 30, 2026, compared to a $6.1 million loss in the prior year period. Cash and cash equivalents increased to approximately $19.9 million as of June 30, 2026. The company filed a U.S. composition of matter patent application for a new form of brilaroxazine seeking accelerated review to extend exclusivity through 2046. FDA feedback on incorporating this formulation into the RECOVER-2 Phase 3 trial and future New Drug Application is expected in Q4 2026, with patient enrollment anticipated in the first half of 2027 subject to additional financing. Reviva Pharmaceuticals Holdings is a late-stage biopharmaceutical company developing therapies for central nervous system, inflammatory, and cardiometabolic diseases.